# A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

Study · id `cardio:ct-nct01643330` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01643330](<https://clinicaltrials.gov/study/NCT01643330>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01643330

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 250 participants.

## Technical summary

Registry record NCT01643330. Randomized; quadruple masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2015-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 250 participants (enrolled count; ClinicalTrials.gov record NCT01643330, source copy `cardio:ctgov-nct01643330-2016-03-24`, retrieved 2026-10-26)
- Start date: 2012-07 (registry gives no type) (ClinicalTrials.gov record NCT01643330, source copy `cardio:ctgov-nct01643330-2016-03-24`, retrieved 2026-10-26)
- Primary completion: 2015-02 (actual) (ClinicalTrials.gov record NCT01643330, source copy `cardio:ctgov-nct01643330-2016-03-24`, retrieved 2026-10-26)
- Completion: 2016-02 (actual) (ClinicalTrials.gov record NCT01643330, source copy `cardio:ctgov-nct01643330-2016-03-24`, retrieved 2026-10-26)
- Countries: United States; Belgium; Denmark; Germany; Hungary; Israel; Netherlands; Poland; Sweden; United Kingdom (ClinicalTrials.gov record NCT01643330, source copy `cardio:ctgov-nct01643330-2016-03-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01643330-2016-03-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure
- Acronym: CUPID-2b
- Condition: Ischemic Cardiomyopathy
- Condition: Non-ischemic Cardiomyopathy
- Condition: Heart Failure
- Condition: Cardiomyopathies
- Intervention (Genetic): AAV1/SERCA2a (MYDICAR)
- Intervention (Genetic): Placebo
- Lead sponsor: Celladon Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial (`cardio:pubmed-26803443`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e0aa41624e727bfa1cfc123030926bdc70aaee9e924a92799845f4822da3a6be
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
